Skip to main content
. 2023 Jan 9;14:100188. doi: 10.1016/j.jpi.2023.100188

Table 2.

Histopathology evaluation of study cases by GSM or WSI.

N (%) %
GSM
Lymphoma (any) 55 65.5
Inflammatory/Infectious/Reactive 21 25
Metastatic disease 8 9.5
Total 84 100



WSI
Lymphoma (any) 57 67.9
Inflammatory/Infectious/Reactive 21 25
Metastatic disease 6 7.1
Total 84 100